











	Definition	Wording to use
<b>Class I</b>	Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.	Is recommended or is indicated
<b>Class II</b>	Conflicting evidence and/or a divergence of opinion about the usefulness/ efficacy of the given treatment or procedure.	
Class IIa	Weight of evidence/opinion is in favour of usefulness/efficacy.	Should be considered
Class IIb	Usefulness/efficacy is less well established by evidence/opinion.	May be considered
<b>Class III</b>	Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.	Is not recommended


Level of evidence A	Data derived from multiple randomized clinical trials or meta-analyses.
Level of evidence B	Data derived from a single randomized clinical trial or large non-randomized studies.
Level of evidence C	Consensus of opinion of the experts and/or small studies, retrospective studies, registries.



## Cardio-Oncology Care Pathways



### Baseline CV toxicity risk assessment checklist




#### Clinical assessment


- Cancer treatment history
- CV history
- CVRF
- Physical examination
- Vital signs measurement<sup>a</sup>

#### Complementary tests


- BNP or NT-proBNP<sup>b</sup>
- cTn<sup>c</sup>
- ECG
- Fasting plasma glucose / HbA1c
- Kidney function / eGFR
- Lipid profile
- TTE<sup>d</sup>



[Redacted]	
[Redacted]	[Redacted]
[Redacted]	
[Redacted]	[Redacted]






























	Green	Blue
	Green	Light Blue
	Yellow	Light Blue
	Green	Light Blue




Baseline clinical CV assessment (physical exam and ECG) is recommended in all cancer patients scheduled for cytotoxic therapies.

	Patient risk level	TTE <sup>1</sup>	NP	cTn
Antiarrhythmics	Very high risk Moderate risk	Class I	Class II	Class II
HER2-targeted therapies <sup>2</sup>	Very high risk Moderate risk	Class I	Class II	Class II
Fluoropyrimidines	Other conditions	Class I		
VEGF	Very high risk Moderate risk Low risk	Class I Class II	Class II	
Second- and third-generation BCR-ABL1 TKI	Other conditions	Class II		
BTK inhibitors	Very high risk	Class I		
PI3K	Very high risk Moderate risk	Class I	Class II	
RAF and MEK inhibitors	Very high risk Moderate risk	Class I		
ICI	Very high risk Other conditions	Class I	Class II	Class I
Quinercetin	Other conditions	Class I		
CAK1 and III	Previous CVD Other conditions	Class I	Class I	Class I
→ to a volume including the heart	Previous CVD	Class II		
TSCT	Other conditions	Class I	Class II	

Very high risk  
  Moderate risk  
  Low risk  
  Other conditions  
  Class I  
  Class II  
  Class III










## Primary and secondary cancer-therapy related CV toxicity prevention strategies

### Primary vs secondary prevention



Management of CVD and CVRF according to ESC Guidelines



In patients at high and very high risk of CTRCD

Minimize the use of cardiotoxic drugs

ACE-I/ARB and beta-blockers

Dexrazoxane/liposomal anthracyclines (patients treated with anthracyclines)

Statins



Class I




Class IIa






### Anthracycline chemotherapy surveillance protocol






# HER2-targeted therapy surveillance protocol




	Green	Blue
	Green	Blue
	Orange	Light Blue
	Yellow	Light Blue








### VEGFi-related cardiovascular toxicities



## VEGFi surveillance protocol











### BCR-ABL TKI-related cardiovascular toxicities




## Second and third generation BCR-ABL TKI surveillance protocol






	Yellow	Light Blue
	Green	Light Blue
	Yellow	Light Blue
	Orange	Light Blue
	Orange	Light Blue





## Proteasome inhibitors surveillance protocol



	Green	Light Blue
	Yellow	Light Blue
	Green	Light Blue
	Yellow	Light Blue
	Yellow	Blue
	Green	Blue





## Risk factors for venous thromboembolic events in patients with multiple myeloma


### Patient-related risk factors


- Previous VTE
- Acute infections
- Autoimmune disease
- Central venous catheter
- Chronic renal disease
- Cigarette smoking
- CVD
- DM
- General surgery
- History of inherited thrombophilia
- Immobilization, surgery, trauma
- Obesity (BMI >30 kg/m<sup>2</sup>)



### Myeloma-related risk factors

- Advanced disease status
- Erythropoietin-stimulating agents
- High dexamethasone doses
- Hyper-viscosity state
- Thalidomide/lenalidomide/ponalidomide








	Green	Blue
	Green	Blue
	Orange	Light Blue
	Yellow	Blue
	Green	Light Blue
	Orange	Light Blue

# Immune checkpoint inhibitors surveillance protocol



### Androgen deprivation therapy-related cardiovascular toxicities

	HTN	HG/DM	HF	IHD/MI	AF	↑QTc
<b>GnRH agonist</b>						
Goserelin	•	⊙	⊙	⊙		•
Fistralin		⊙				•
Leuprolerin	•					•
Triptorelin	⊙	•				•
<b>GnRH antagonist</b>						
Ezogarelix	•	•	•	•	•	•
Kelugarelix		⊙	•	•		•
<b>1<sup>st</sup> generation antiandrogens</b>						
Firaparimide	⊙	⊙	⊙	⊙		•
Flutamide	•					•
Nitaramide	⊙	⊙	⊙	⊙		•
<b>2<sup>nd</sup> generation androgen deprivation therapy</b>						
Apalutamide	⊙	⊙	⊙	⊙		•
Enzalutamide	•		⊙	⊙		•
Ezatalutamide	⊙			⊙		•
<b>Androgen metabolism inhibitor</b>						
Abiraterone <sup>a</sup>	⊙	⊙	⊙	⊙	⊙	•

 Very common: ≥ 10% incidence     
  Common: ≥ 1% to < 10% incidence

 Common: 1% to < 10% incidence     
  Rare: < 1% incidence

 Rare: < 0.1% incidence






	Green	Teal
	Green	Blue-Gray
	Yellow	Light Blue




### ALK inhibitor- and EGFR inhibitor-related cardiovascular toxicities












### Cardiovascular surveillance in patients referred for haematopoietic stem cell transplantation






















	Green	Light Blue
	Green	Light Blue
	Yellow	Dark Blue
	Green	Light Blue













	Yellow	Light Blue
	Green	Light Blue
	Yellow	Light Blue
	Green	Light Blue

	Green	Light Blue
	Green	Blue
	Red	Light Blue










## Pathophysiology of AF associated with cancer



Structured approach to anticoagulation for AF in patients with cancer














[Redacted]			
[Redacted]			
[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]






	Green	Light Blue
	Green	Light Blue



## Recommended threshold for asymptomatic hypertension treatment in different clinical scenarios

Home BP mmHg	CS	Curable cancer during treatment	Metastatic cancer Prognosis >3 years	Metastatic cancer Prognosis 1–3 years	Metastatic cancer Prognosis <1 year
160+	Treat	Treat	Treat	Treat	Treat
140–159	Treat	Treat	Treat	Consider treatment	May treat
135–139	Treat	May treat	Consider treatment	May treat	None
130–134	May treat	None	None	None	None
<130	None	None	None	None	None

● Class I   
 ● Class IIa   
 ● Class IIb





	Green	Blue
	Green	Light Blue
	Green	Light Blue
	Red	Light Blue



## Risk factors for VTE in patients with cancer


### Patient-related factors

- Ageing
- Comorbidities<sup>a</sup>
- Sex (female)
- Hereditary coagulation defects<sup>b</sup>
- Performance status
- Prior VTE history



### Cancer-related factors


- Cancer type
- Genetic characteristics (JAK2 or K-ras mutations)
- Histology (adenocarcinoma)
- Initial period after diagnosis
- Primary site (pancreas, stomach, ovaries, brain, lung, myeloma)
- Stage (advanced, metastatic)



### Treatment-related factors

- Cancer therapy<sup>c</sup>
- Central venous catheters
- Hospitalization
- Major surgery





	Green	Teal
	Green	Teal
	Orange	Light Blue
	Yellow	Teal
	Green	Light Blue

	Green	Blue
	Green	Blue
	Orange	Blue
	Green	Light Blue














	Green	Light Blue
	Green	Light Blue
	Green	Blue
	Green	Blue
	Yellow	Blue

	Orange	Light Blue
	Green	Light Blue
	Orange	Light Blue
	Yellow	Blue




	Green	Blue
	Green	Light Blue
	Green	Light Blue
	Yellow	Blue
	Yellow	Blue

				1
















**Pulmonary artery**

- Sarcoma

**Right atrium**

- Lipoma
- Lymphoma
- Metastasis
- Myxoma
- Sarcoma

**Right ventricle**


- Fibroma
- Lipoma
- Lymphoma
- Metastasis
- Rhabdomyoma

**Inferior cava vein**

- Leiomyoma
- Renal tumour

**Pericardium**

- Lipo sarcoma
- Lipoma
- Lymphoma
- Mesothelioma
- Metastasis


**Left atrium**

- Lipoma
- Metastasis
- Myxoma
- Sarcoma

**Pulmonary veins**


- Lung tumours
- Sarcoma

**Valves**


- Fibroelastoma
- Metastasis

**Left ventricle**

- Fibroma
- Lipoma
- Lymphoma
- Metastasis
- Rhabdomyoma
- Sarcoma













	Green	Light Blue
	Yellow	Light Blue
	Green	Light Blue

## Carcinoid heart disease: clinical features and diagnostic tests

### Clinical features



### Diagnostic and prognostic tools



CMR

TTE

Circulating serotonin

NP

Urinary 5HIAA

## Non-invasive diagnosis of AL-CA

### Clinical features

#### Skin

- Bruising

#### CV

- AF/flutter
- Dyspnoea
- LHFpEF or unexplained right HF
- Hypotension or syncope
- Peripheral oedema

#### Nerves

- Orthostatic hypotension
- Peripheral polyneuropathy
- Polyneuropathy

#### Kidney

- Proteinuria
- Renal impairment

#### GI

- Constipation/diarrhoea
- Macroglossia
- Malabsorption/weight loss/nausea

### Investigations

Laboratory<sup>a</sup>


ECG<sup>b</sup>

TTE<sup>c</sup>

ECHO score  $\geq 8$ <sup>d</sup>

Characteristic echo findings<sup>e</sup>


CMR<sup>f</sup>








# Assessing risk of RT to CIED


Patient









## Interaction between healthcare professionals and patients with cancer



## The role of scientific societies in the promotion and development of cardio-oncology






**2022 ESC Pocket Guidelines**  
Clinical Practice Guidelines Committee

**CARDIO-ONCOLOGY**  
Guidelines on cardio-oncology

 ESC  
European Society of Cardiology



**2022 ESC Pocket Guidelines**  
Clinical Practice Guidelines Committee

**CARDIO-ONCOLOGY**  
Guidelines on cardio-oncology


 ESC  
European Society of Cardiology

**2022 ESC Guidelines on cardio-oncology**  
Clinical Practice Guidelines


**Recommendations for a generic approach to cardiovascular toxicity risk ESC categorization (1)**

Recommendation	Class	Level
Oral bisphosphonates or clodronate should be used to prevent or reduce therapy-related osteoporosis in all patients with cancer.	I	A
Continuing the use of the 20-weeks treatment for patients with cancer-related heart failure is recommended.	I	C
The use of HMG-CoA reductase inhibitors should be considered to reduce the risk of statin-associated myopathy in patients with cancer.	IIa	B
The use of statins should be considered to reduce the risk of statin-associated myopathy in patients with cancer.	IIb	B

**Figure 1**  
Dynamics of cardiovascular toxicity risk of patients with cancer over their therapy continuum



**Available available in the European Heart Journal website and the ESC Pocket Guidelines App**



**2022 Essential messages from ESC Guidelines**  
Clinical Practice Guidelines Committee

**CARDIO-ONCOLOGY**  
Guidelines on cardio-oncology

 ESC  
European Society of Cardiology